29 October 2026
Merck beats forecasts as its under-the-skin Keytruda shot takes off
Merck's third-quarter sales rose 5% to $18.09 billion, with its cancer drug Keytruda bringing in $8.6 billion, and the company raised its full-year adjusted profit outlook.
Merck's biggest drug is getting a second act before its first one ends. On Thursday the drugmaker beat Wall Street's third-quarter forecasts, helped by its cancer medicine Keytruda and especially by a newer version of it that patients get as a quick injection under the skin.
What happened
Revenue rose 5% from a year earlier to $18.09 billion, above the $17.31 billion analysts expected in an LSEG survey. Adjusted earnings, which leave out acquisition and restructuring costs, were $2.49 a share versus $2.08 expected. On the standard accounting measure, net income fell to $5.07 billion from $5.79 billion a year earlier.
Keytruda alone brought in $8.60 billion, nearly half of all Merck's sales and well above the $7.73 billion analysts expected, according to StreetAccount. That total includes $830 million from Keytruda Qlex, the injectable form launched in 2025, which had its best quarter yet and beat a $649 million estimate.
- Gardasil, the HPV vaccine, sold about $2 billion on stronger US demand, after a weak patch last year tied to excess stock and soft demand in China.
- Winrevair, for a rare and deadly lung condition, grew 93% to $694 million.
- The animal health business came in a little below estimates at $1.68 billion.
Merck raised its adjusted profit outlook to $2.77 to $2.82 a share, from $2.66 to $2.76, a figure that now includes a $400 million charge for a licensing deal with Chinese cancer drugmaker SciBrunch. It also lifted the bottom of its 2026 revenue range, which is now $66.8 billion to $67.3 billion.
Why it matters
Key Keytruda patents start to expire in 2028. A patent gives a company the sole right to sell a drug for a set time; once it lapses, rivals can sell cheaper copies, and sales of the original usually drop fast. For a drug that makes up close to half of Merck's revenue, that is the single biggest risk to the business.
Qlex is a large part of Merck's answer. The plan is to move patients from the original version, given through a drip into a vein, to the more convenient shot, which is protected for longer. Merck has also been striking deals to add new drugs before 2028 arrives. The company was worth about $350 billion at Tuesday's close, according to Noorult data.
What to watch
- How quickly Qlex sales keep climbing, the clearest sign of whether patients are switching over.
- More deals as Merck tries to fill the gap Keytruda copies will leave.
- Whether Gardasil's recovery holds now that US demand has picked up.
Merck's full financials are on its Noorult company page.
The companies in this story
Based on reporting by CNBC: Merck (MRK) earnings Q3 2026. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion